Home
Biohaven

Biohaven Market Share Analysis for August 2026

DescriptionHarnessing the boundless potential of scientific innovation to transform the treatment of neurological and neuropsychiatric diseases. Summarized from the website

Health > Biotechnology and Pharmaceuticals

Domainbiohaven.com

Year Founded2022

Employees201 - 500

Annual Revenue--

Biohaven

Biohaven (including company regionals)

biohaven.com

See more website traffic and engagement information

Total visits to Biohaven's top domains

Understand Biohaven market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

biohaven.com11.3K

See more with Sales Intelligence

Avg. visit duration in Biohaven's top domains

Analyze Biohaven engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

biohaven.com00:01:01

See more with Sales Intelligence

Avg. pageviews on Biohaven's top domains

See how Biohaven keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

biohaven.com2.21

See more with Sales Intelligence

Biohaven top competitors by domain

Top similar sites in August 2026, ranked by their affinity

royaltypharma.comCompany NameRoyalty PharmaEmployees51 - 200HQUnited States, New York, New York CityAnnual revenue> $1BTotal visits8.1KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Biohaven

These are the website technologies, by industry, used by Biohaven top domains

Widget (5)

Yoast SEO

Content Management System (3)

WordPress

Marketing (3)

Google Marketing Platform

Conversion & Analytics (2)

Google Analytics

More Technologies

9

See all

News & Signals from Biohaven

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBiohaven Ltd. hires John Yetimoglu as board.Recent corporate announcements, such as Biohaven appointing technology investor John Yetimoglu to its board, highlight a broader market reality: traditional industries are rapidly absorbing frontier artificial intelligence and deep-tech scaling strategies.

NewsBiohaven Ltd. will attend event ESMO Congress on Oct 23rd '26.Biohaven to present new clinical data at ESMO Congress on BHV-1530, a novel fgfr3-directed ADC with a proprietary topoisomerase I (TopoIx) payload.